Interventional Radiology for Uterine Fibroids

Uterine artery embolization, the flagship interventional radiology procedure for fibroids, relieves heavy bleeding, pain, and bulk-related pressure in the vast majority of women who undergo it, with research consistently reporting symptom improvement in roughly 80 to 90 percent of cases.¹ The procedure is performed not by a gynecologist but by an interventional radiologist, a physician who uses real-time imaging to guide catheters and other instruments through blood vessels or directly into tissue. For fibroids specifically, the field offers more than one tool, though embolization remains far and away the most studied.

What Happens During Uterine Artery Embolization

An interventional radiologist threads a thin catheter through a small puncture, usually at the wrist or groin, and navigates it under X-ray guidance into the uterine arteries that feed the fibroids. Tiny particles called embolic agents are injected into those arteries, blocking blood flow to the fibroids while largely sparing the surrounding uterine tissue. Starved of oxygen and nutrients, the fibroids undergo a slow death and gradually shrink over the following weeks and months. The uterus itself recovers because it has collateral blood supply from other vessels.²

The whole procedure usually takes about an hour and is done under conscious sedation rather than general anesthesia. Most women stay in the hospital overnight, though some centers discharge patients the same day after a few hours of monitoring and pain management.

How Much Do Fibroids Shrink

Fibroid shrinkage varies, but most studies show substantial reductions within six months. In one early prospective study, the average fibroid volume dropped by about two-thirds at the six-month mark.³ The Ontario Uterine Fibroid Embolization Trial found more modest but still meaningful reductions: a median drop of about 35 percent in overall uterine volume and 42 percent in the dominant fibroid’s volume.⁴ The spread reflects differences in fibroid type, size, and blood supply rather than inconsistency in the procedure itself.

What matters more to most patients than the shrinkage number on an MRI scan is whether symptoms actually improve. In the Ontario trial, around 83 percent of women reported meaningful improvement in heavy menstrual bleeding, 77 percent saw improvement in pain, and 86 percent experienced relief from urinary frequency and urgency. Average menstrual duration dropped from about seven and a half days to just over five. Satisfaction rates were high: 91 percent said they were satisfied with the treatment.⁵ One interesting finding from that trial was that improvement in heavy bleeding did not depend on how large the uterus was before the procedure or how much it shrank afterward, suggesting that embolization can work well even when the fibroids remain sizeable.

How Embolization Compares to Surgery

For women weighing their options, the big question is usually whether embolization delivers results as good as a myomectomy (surgical removal of fibroids) or hysterectomy (removal of the uterus). The honest answer is that surgery, particularly hysterectomy, tends to produce slightly better symptom scores, but embolization comes remarkably close while offering a faster and easier recovery.

In a large registry comparison, all three procedures produced substantial quality-of-life gains at one year. Hysterectomy patients reported the highest quality-of-life scores and lowest remaining symptom burden, but myomectomy and embolization patients reported comparable symptom relief to each other.⁶ A randomized trial specifically comparing embolization and myomectomy found equal quality-of-life improvements in both groups by one year.⁷ A later, larger randomized trial published in the New England Journal of Medicine found a modest advantage for myomectomy at two years, with an adjusted quality-of-life difference of about 6 to 8 points on a 100-point scale.⁸

Where embolization clearly wins is recovery time. One randomized trial found a median hospital stay of just one day for embolization versus five days for surgery, along with a significantly shorter time before returning to work.⁹ When compared specifically to hysterectomy in the Dutch EMMY trial, the hospital stay averaged about two and a half days for embolization versus five for hysterectomy.¹⁰

The complication profile is also different. A systematic review and meta-analysis found that embolization carried a lower risk of major complications compared to surgical options but a higher rate of minor ones.¹¹ In the New England Journal of Medicine trial, perioperative and postoperative complications occurred in about 24 percent of embolization patients versus 29 percent of myomectomy patients.¹² So the trade-off is real but modest: embolization gets you back on your feet faster with fewer serious complications, while surgery may edge it out on longer-term symptom control.

Recovery and Post-Embolization Syndrome

The first 24 to 48 hours after embolization are the most uncomfortable part. When fibroids lose their blood supply, they trigger cramping, pelvic pain, nausea, fatigue, and sometimes low-grade fever. This cluster of symptoms has its own name: post-embolization syndrome. It is expected and not a sign that something has gone wrong, but it can be intense enough to require strong pain medication, often delivered through an IV in the hospital. Most women feel substantially better within a week and are back to normal activities within two to three weeks.

Not everyone experiences the syndrome to the same degree. A recent study found that about 48 percent of patients developed clinically significant post-embolization syndrome, and that women who had never been pregnant were more likely to experience it. Older age appeared to offer some protection, though the trend fell just short of reaching statistical significance.¹³

Other Possible Complications

Beyond post-embolization syndrome, there are a handful of complications that come up in the literature:

Fibroid expulsion: Sometimes a dying fibroid detaches from the uterine wall and passes through the cervix. Reported rates range widely, but most estimates land around 5 to 15 percent. Fibroids that are submucosal (bulging into the uterine cavity) or pedunculated (attached by a stalk) are at higher risk.¹⁴
Amenorrhea: Some women lose their periods temporarily or, more rarely, permanently. This is more likely in women over 45 and is related to effects on ovarian function, discussed below.
Vaginal discharge: A prolonged watery or brownish discharge can occur for weeks as the fibroids break down. It is usually harmless but can be bothersome.
Infection: Rare, but it can happen when necrotic fibroid tissue becomes a breeding ground for bacteria. Fever beyond the first few days warrants a call to your doctor.
Access-site injury: Small risks related to the catheter puncture site, such as bruising or, very rarely, a damaged blood vessel.¹⁵

Long-Term Durability and Reintervention

This is where the picture gets more complicated and where honest conversations between patients and doctors matter most. Embolization preserves the uterus, which means fibroids can potentially regrow from tissue that was not fully devascularized, or new fibroids can develop. Some women will eventually need a second procedure.

The REST trial, a randomized comparison between embolization and surgery, found that the five-year intervention rate for treatment failure or complications was 32 percent in the embolization arm versus just 4 percent in the surgery arm.¹⁶ That gap sounds alarming, but context helps: “surgery” in that trial was mostly hysterectomy, which eliminates recurrence by removing the entire organ. Comparing apples to apples, a large claims-based study estimated five-year reintervention rates of about 19 percent for myomectomy and 24 percent for embolization.¹⁷ A meta-analysis of uterine-sparing procedures put the five-year reintervention rate at roughly 12 percent for myomectomy and 14 percent for embolization, which are closer than many people assume.¹⁸

The takeaway: if you keep your uterus, there is a real chance you will need further treatment down the line regardless of whether you choose embolization or myomectomy. That is not a failure of the procedure; it is the nature of fibroids.

Fertility and Pregnancy After Embolization

Fertility is often the most emotionally charged part of the conversation. UAE preserves the uterus, but that does not automatically make it the best choice for someone planning to become pregnant. Most professional guidelines still recommend myomectomy as the preferred uterine-sparing option when future fertility is a priority.

A review comparing reproductive outcomes found that pregnancies after myomectomy generally had higher rates of clinical pregnancy and live birth, and lower rates of miscarriage, abnormal placentation, preterm labor, and malpresentation, compared to pregnancies after embolization.¹⁹ That said, the evidence base here is limited and mostly observational. A more recent meta-analysis that pooled data from randomized trials found no statistically significant differences between the two procedures in pregnancy rates, live births, miscarriage, or induced termination, though the confidence intervals were wide, reflecting small sample sizes.²⁰

The honest state of things is that we lack a large, well-powered randomized trial specifically designed to settle the fertility question. The data we have leans in favor of myomectomy, but with more uncertainty than many doctors let on. For women who are not surgical candidates or strongly prefer to avoid surgery, successful pregnancies after embolization are well documented. It just comes with caveats that should be discussed with both your interventional radiologist and your obstetrician.

Effects on Ovarian Function

A concern that does not always get enough airtime is whether embolization can harm the ovaries. The embolic particles are targeted at the uterine arteries, but some of the blood supply to the ovaries can share branches with those arteries, meaning a small amount of particle flow to the ovaries is possible. A randomized study comparing embolization and hysterectomy found that both procedures affected ovarian reserve and that older women were more likely to enter menopause after either procedure.²¹

Recent research has offered some reassurance for younger women. A small cohort study of patients who underwent combined uterine and ovarian artery embolization for adenomyosis (a related condition) found that a key marker of ovarian reserve dropped temporarily at three months but recovered fully by six months and remained stable at one year.²² All patients in that study resumed regular periods without menopausal symptoms. The group was young, though, and the sample was small, so these findings need confirmation in larger studies. For women over 45, the risk of accelerated menopause after embolization is a genuine consideration.

Who Is a Good Candidate

Not every woman with fibroids is a good fit for embolization. Before the procedure, an MRI is typically performed to assess fibroid number, size, location, blood supply, and whether any fibroid characteristics might predict a poor response. MRI can also help distinguish fibroids from conditions that mimic them, like adenomyosis or, very rarely, a uterine sarcoma.²³ Characteristics like signal intensity on different MRI sequences are increasingly used to predict which fibroids will respond well and which may not shrink much.²⁴

Pedunculated subserosal fibroids, those that hang off the outside of the uterus on a stalk, were once considered a contraindication because of fears the stalk could lose its blood supply and the fibroid could detach dangerously. A meta-analysis has since challenged that view, finding an adverse event rate of under 2 percent and a devascularization rate of about 76 percent for these fibroids, suggesting they can be treated safely in selected cases.²⁵

The strongest candidates for embolization tend to be women who want to keep their uterus, do not plan a pregnancy in the near future, have multiple or large fibroids that would make myomectomy complex, or want to avoid the risks and recovery of open surgery.

Other Interventional Radiology Approaches

Embolization is the most established IR procedure for fibroids, but it is not the only one. Two other technologies are worth knowing about.

MRI-guided focused ultrasound, sometimes called MRgFUS or HIFU, uses focused sound waves to heat and destroy fibroid tissue while a patient lies inside an MRI scanner. No needles, no catheters, no incisions. It is a genuinely noninvasive treatment that can improve quality of life and reduce fibroid size.²⁶ The main limitation is that retreatment rates have historically been higher than for embolization, particularly in earlier studies when the amount of fibroid tissue that could be safely ablated was limited by regulatory restrictions. Later protocols allowing more extensive ablation brought retreatment rates down.²⁷ Availability remains limited: not every medical center has the equipment, and not every fibroid is in a safe location for ultrasound treatment.

Radiofrequency ablation inserts a small probe, guided by ultrasound or laparoscopy, directly into the fibroid and uses heat to destroy it from the inside. Evidence for safety and efficacy has been growing, with low complication rates reported across studies.²⁸ It is still a newer option relative to embolization and does not yet have the same depth of long-term outcome data, but it is increasingly appearing in treatment discussions.

Sexual Function and Body Image

A question women sometimes hesitate to ask is whether treatment will affect their sex life. A randomized comparison of embolization and hysterectomy found no significant differences between the two groups in sexual pleasure, discomfort during intercourse, or body image scores over two years of follow-up. By 24 months, the embolization group actually reported less discomfort during sex, more frequent intercourse, and better body image compared to their own baseline. The hysterectomy group also improved, though the changes did not reach statistical significance.²⁹ For many women, fibroids themselves are the problem: heavy bleeding, bloating, and pelvic pain take a toll on intimacy, and treating the fibroids tends to help regardless of the method.

Cost and Access

Embolization has repeatedly been shown to be cost-effective compared to hysterectomy, partly because of the shorter hospital stay and faster return to work. One cost-effectiveness analysis found that embolization produced slightly more quality-adjusted life years at lower overall cost than hysterectomy.³⁰

Despite that, access is uneven. Embolization is performed by interventional radiologists, not gynecologists, and many women first learn about fibroids from their gynecologist. If the gynecologist does not mention embolization as an option, or if the closest interventional radiology practice is hours away, the procedure effectively does not exist for that patient. Racial and ethnic disparities complicate the picture further. A recent analysis found that compared to white patients, Black patients were more likely to undergo embolization over hysterectomy but less likely to undergo embolization over myomectomy. Hispanic patients were less likely to receive embolization compared to surgical options overall.³¹ The Society of Interventional Radiology has acknowledged the lack of research on health equity in fibroid care and has called for more attention to how disparities influence the treatments patients are offered.³²

Innovations on the Horizon

The field is not standing still. Newer embolic materials, including hydrophobic injectable liquids, are being developed alongside procedural refinements like transradial access, where the catheter enters through the wrist instead of the groin. Transradial access allows patients to sit up and walk sooner, reducing discomfort and potentially enabling same-day discharge more reliably.³³ MRI sequences used for preprocedural planning are also improving, with parameters like diffusion-weighted imaging playing an emerging role in predicting which fibroids will respond best to embolization.³⁴ These are incremental advances, not revolutionary breakthroughs, but they collectively point toward a future where the procedure is more comfortable, more precisely targeted, and available to more women than it is today.